アジア太平洋地域の運動失調症市場、タイプ別(脊髄小脳失調症、毛細血管拡張性運動失調症、発作性運動失調症、その他(多系統萎縮症(MSA)))、製品別(治療と診断)、剤形別(固形、液体、その他)、投与経路別(経口、非経口、その他)、患者タイプ別(成人、小児、高齢者)、エンドユーザー別(病院、診療所、在宅医療、その他)、流通チャネル別(直接入札、小売販売、その他) - 2029年までの業界動向と予測。
アジア太平洋市場の分析と洞察
運動失調症の罹患率の増加により、市場の需要が高まっています。より良い医療サービスを求める医療費の増加も、市場の成長に貢献しています。この重要な時期に、主要な市場プレーヤーは製品の発売と承認に非常に注力しています。さらに、政府と規制当局は、急増する新興疾患に対する製品承認によって市場プレーヤーをサポートしています。
アジア太平洋の運動失調症市場は、市場プレーヤーの増加と高度な製品の利用可能性により、予測年度に成長しています。これに伴い、メーカーは市場に新しい製品を投入するための研究開発活動に取り組んでいます。運動失調症治療の分野での研究の増加と、アルコール消費と薬物使用の増加により、市場の成長がさらに促進されると予想されます。ただし、一部の発展途上国では病気の診断が難しく、遺伝子検査施設が不足しているため、予測期間中のアジア太平洋の運動失調症市場の成長が妨げられる可能性があります。
医療費の増加と市場プレーヤーによる戦略的取り組みにより、市場には治療を強化する機会がもたらされる可能性があります。ただし、医薬品や製品の承認に関連する厳格な規則や規制、さまざまな企業による製品リコールが、市場の成長を妨げると予想されます。
アジア太平洋地域の運動失調症市場は、2022年から2029年の予測期間に市場成長が見込まれています。データブリッジマーケットリサーチは、市場は2022年から2029年の予測期間に7.8%のCAGRで成長し、2021年の4,443.95千米ドルから2029年には7,734.86千米ドルに達すると分析しています。
レポートメトリック |
詳細 |
予測期間 |
2022年から2029年 |
基準年 |
2021 |
歴史的な年 |
2020 |
定量単位 |
収益は1000米ドル、価格は米ドル |
対象セグメント |
タイプ別(脊髄小脳失調症、毛細血管拡張性運動失調症、発作性運動失調症、その他(多系統萎縮症(MSA)))、製品別(治療および診断)、剤形別(固形剤、液体剤、その他)、投与経路別(経口剤、非経口剤、その他)、患者タイプ別(成人、小児、高齢者)、エンドユーザー別(病院、診療所、在宅医療、その他)、流通チャネル別(直接入札、小売販売、その他) |
対象国 |
中国、日本、インド、韓国、オーストラリア、シンガポール、タイ、マレーシア、インドネシア、フィリピン、ベトナム、その他のアジア太平洋諸国 |
対象となる市場プレーヤー |
Novartis AG、Merck KGaA、Aurobindo Pharma、Pfizer Inc.、Sanofi、Teva Pharmaceutical Industries Ltd.、Viatris Inc.、Sun Pharmaceutical Industries Ltd.、Lupin、Amneal Pharmaceuticals LLC.、Apotex Inc.、Cipla Inc.、Reata Pharmaceuticals, Inc.、Biohaven Pharmaceuticals など |
市場の定義
運動失調症は、協調運動、バランス、発話に影響を及ぼす一連の障害を指す用語です。どの部位にも影響が出る可能性がありますが、運動失調症の人はバランス、歩行、発話、嚥下、および書くこと、食べること、視覚など高度な制御を必要とする作業に困難を抱えることがよくあります。正確な症状とその重症度は、患者の運動失調症の種類によって異なります。
運動失調症は通常、脳の小脳と呼ばれる部分の損傷によって起こりますが、神経系の他の部分の損傷によっても起こることがあります。この損傷は、MS (多発性硬化症) などの基礎疾患の一部である場合もあれば、頭部外傷、脳への酸素不足、長期にわたる過度のアルコール摂取によって起こる場合もあります。遺伝性運動失調症は、影響を受けるかどうかは不明ですが、家族から受け継がれた欠陥遺伝子によって引き起こされます。
アジア太平洋の運動失調症市場の動向
ドライバー
- 運動失調症の有病率と発症率の増加
運動失調症は、運動と協調性に影響を与える神経系に関連する神経疾患の用語です。運動失調症の人は、バランス、協調性、嚥下、発話に問題を抱えることがよくあります。運動失調症は通常、運動を調整する小脳である脳の一部が損傷することで発症します。これはまれな病気ですが、その発症は世界中で非常に蔓延しています。この病気は世界中で大きな臨床問題として広く認識されており、罹患率と死亡率の負担が大きくなっています。したがって、さまざまな年齢層に影響を与える運動失調症の有病率と発症率の増加が、アジア太平洋地域の運動失調症市場を牽引しています。
- 運動失調症治療の分野における急速な研究
運動失調症には、非常に多くの危険因子が報告されています。したがって、運動失調症に関連する危険因子と症状を軽減するために、運動失調症治療の分野でさまざまな研究が行われています。市場におけるさまざまな種類の運動失調症を治療するために、政府による資金援助も開始されています。運動失調症治療の分野でのさまざまな急速な研究は、予測期間中に市場を牽引し、同治療の研究開発の大幅な成長を予測するのに役立ちます。
機会
- 医療費の増大
各国の人々の可処分所得が増加しているため、医療費は世界中で増加しています。さらに、人口の要件を満たすために、政府機関と医療機関は医療費の加速化によって主導権を握っています。医療費の増加は、同時に、近年この疾患が非常に蔓延しているため、医療現場が運動失調症の治療施設を改善するのにも役立ちます。
また、主要な市場プレーヤーが講じる戦略的取り組みは、2022~2029年の予測期間において、運動失調症市場に構造的完全性と将来の機会をもたらすでしょう。
制約/課題
しかし、一部の発展途上国では病気の診断が難しく、遺伝子検査施設も不足しているため、運動失調症市場の成長率は低下するでしょう。さらに、厳しい規則や規制が予測期間の市場にさらなる課題をもたらすでしょう。
このアジア太平洋の運動失調症市場レポートでは、最近の新しい開発、貿易規制、輸出入分析、生産分析、バリュー チェーンの最適化、市場シェア、国内および現地の市場プレーヤーの影響、新たな収益源の観点から見た機会の分析、市場規制の変更、戦略的市場成長分析、市場規模、カテゴリ市場の成長、アプリケーションのニッチと優位性、製品の承認、製品の発売、地理的拡大、市場における技術革新などの詳細が提供されます。アジア太平洋の運動失調症市場に関する詳細情報を取得するには、アナリスト ブリーフについて Data Bridge Market Research にお問い合わせください。当社のチームが、市場の成長を達成するための情報に基づいた市場決定を行うお手伝いをいたします。
COVID-19後のアジア太平洋の運動失調症市場への影響
COVID-19は市場にプラスの影響を与えています。パンデミック中のロックダウンと隔離は、病気の管理と服薬遵守を複雑にします。そのため、さまざまな治療薬が世界の人口に広く増加しています。したがって、パンデミックはこの市場にプラスの影響を与えています。
最近の開発
- 2022年11月、ファイザー社はアリーナ・ファーマシューティカルズの買収を完了したことを発表しました。同社は、いくつかの免疫炎症性疾患を治療するための革新的な潜在的治療法を開発している臨床段階の企業です。この買収により、同社は製品ポートフォリオを拡大することができました。
アジア太平洋の運動失調症市場の範囲
アジア太平洋の運動失調症市場は、タイプ、製品、剤形、投与経路、患者タイプ、エンドユーザー、流通チャネルに分類されています。これらのセグメントの成長は、業界のわずかな成長セグメントの分析に役立ち、ユーザーに貴重な市場概要と市場洞察を提供し、コア市場アプリケーションを特定するための戦略的決定を下すのに役立ちます。
タイプ
- 脊髄小脳失調症
- 毛細血管拡張性運動失調症
- 発作性運動失調症
- その他(多系統萎縮症(MSA))
タイプに基づいて、アジア太平洋地域の運動失調症市場は、脊髄小脳失調症、毛細血管拡張性運動失調症、発作性運動失調症、その他(多系統萎縮症(MSA))に分類されます。
製品
- 診断
- 処理
製品に基づいて、アジア太平洋の運動失調症市場は治療と診断に分類されます。
剤形
- 固体
- 液体
- その他
剤形に基づいて、アジア太平洋地域の運動失調市場は、固体、液体、その他に分類されます。
投与経路
- オーラル
- 非経口
- その他
投与経路に基づいて、アジア太平洋地域の運動失調症市場は、経口、非経口、その他に分類されます。
患者タイプ
- アダルト
- 子供
- 老年病
患者のタイプに基づいて、アジア太平洋地域の運動失調症市場は、成人、小児、高齢者に分類されます。
エンドユーザー
- 病院
- クリニック
- 在宅医療
- その他
エンドユーザーに基づいて、アジア太平洋地域の運動失調症市場は、病院、診療所、在宅医療、その他に分類されます。
流通チャネル
- 直接入札
- 小売販売
- その他
流通チャネルに基づいて、アジア太平洋の運動失調症市場は、直接入札、小売販売、その他に分類されます。
アジア太平洋の運動失調症市場の地域分析/洞察
アジア太平洋地域の運動失調症市場が分析され、国、タイプ、製品、剤形、投与経路、患者タイプ、エンドユーザー、流通チャネル別に市場規模の洞察と傾向が提供されます。
この地域に含まれる国には、中国、日本、インド、韓国、オーストラリア、シンガポール、タイ、マレーシア、インドネシア、フィリピン、ベトナム、その他のアジア太平洋諸国があります。中国は、市場シェアと市場収益の面でアジア太平洋の運動失調症市場を支配すると予想されており、予測期間中もその優位性を維持し続けるでしょう。これは、この地域での運動失調症の有病率が高いためであり、急速な研究開発が市場を後押ししています。
レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。新規および交換販売、国の人口統計、疾病疫学、輸出入関税などのデータ ポイントは、個々の国の市場シナリオを予測するために使用される主要な指標の一部です。さらに、国別データの予測分析を提供する際には、アジア太平洋ブランドの存在と可用性、地元および国内ブランドとの激しい競争により直面する課題、販売チャネルの影響が考慮されています。
競争環境とアジア太平洋の運動失調症市場シェア分析
アジア太平洋の運動失調症市場の競争状況は、競合他社の詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、アジア太平洋の運動失調症市場に対する会社の重点にのみ関連しています。
アジア太平洋地域の運動失調症市場で活動している主要企業としては、ノバルティス AG、メルク KGaA、オーロビンド ファーマ、ファイザー社、サノフィ、テバ製薬工業株式会社、ビアトリス社、サン製薬工業株式会社、ルピン社、アムニール製薬株式会社、アポテックス社、シプラ社、リアタ製薬株式会社、バイオヘイブン製薬などが挙げられます。
研究方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。市場データは、市場統計モデルとコヒーレント モデルを使用して分析および推定されます。さらに、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数の市場への影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。これとは別に、データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、企業市場シェア分析、測定基準、アジア太平洋と地域、ベンダー シェア分析が含まれます。さらに問い合わせる場合は、アナリストへの電話をリクエストしてください。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC ATAXIA MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
4.3 EPIDEMIOLOGY
5 PIPELINE ANALYSIS
6 ASIA PACIFIC ATAXIA MARKET: REGULATORY SCENARIO
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE AND INCIDENCES OF ATAXIA
7.1.2 RAPID RESEARCH IN FIELD OF ATAXIA THERAPEUTICS
7.1.3 RISE IN ALCOHOL AND DRUG USAGE
7.1.4 GROWING NUMBER OF INCIDENCES OF AUTO-IMMUNE DISEASE
7.2 RESTRAINTS
7.2.1 DIFFICULTY IN DIAGNOSIS OF DISEASE
7.2.2 LACK OF GENETIC TESTING IN DEVELOPING COUNTRIES
7.3 OPPORTUNITIES
7.3.1 RISING HEALTHCARE EXPENDITURE
7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.4 CHALLENGES
7.4.1 STRINGENT RULES AND REGULATIONS
7.4.2 PRODUCT RECALL
8 ASIA PACIFIC ATAXIA MARKET, BY TYPE
8.1 OVERVIEW
8.2 SPINOCEREBELLAR ATAXIAS
8.2.1 TYPE 3
8.2.2 TYPE 2
8.2.3 TYPE 1
8.2.4 OTHERS
8.3 ATAXIA-TELANGIECTASIA
8.4 EPISODIC ATAXIA
8.5 OTHERS (MULTIPLE SYSTEM ATROPHY (MSA))
9 ASIA PACIFIC ATAXIA MARKET, BY PRODUCT
9.1 OVERVIEW
9.2 TREATMENT
9.2.1 PHARMACOTHERAPY
9.2.1.1 STIFFNESS/SPASTICITY
9.2.1.1.1 GABAPENTIN
9.2.1.1.2 LEVODOPA
9.2.1.1.3 OTHERS
9.2.1.2 GAIT AND TREMORS
9.2.1.2.1 VARENICLINE
9.2.1.2.2 RILUZOLE
9.2.1.2.3 AMANTADINE
9.2.1.2.4 OTHERS
9.2.1.3 ANTI-OXIDANTS
9.2.1.3.1 N‐ACETYLCYSTEINE
9.2.1.3.2 SELEGILINE
9.2.1.3.3 DEHYDROEPIANDROSTERONE
9.2.1.3.4 VITAMIN E
9.2.1.4 NON ANTI-OXIDANTS
9.2.1.4.1 ERYTHROPOIETIN
9.2.1.4.2 DEFERIPRONE
9.2.1.4.3 RESVERATROL
9.2.1.4.4 HISTONE DEACETYLASE INHIBITORS
9.2.1.5 ANTI-ARRHYTHMIC AGENTS
9.2.1.5.1 AMIODARONE
9.2.1.5.2 PROPAFENONE
9.2.1.5.3 FLECAINIDE
9.2.1.5.4 IBUTILIDE
9.2.1.6 ANTI-CARDIAC FAILURE
9.2.1.6.1 BENAZEPRIL
9.2.1.6.2 LISINOPRIL
9.2.1.6.3 CAPTOPRIL
9.2.1.6.4 ENALAPRIL
9.2.1.6.5 FOSINOPRIL
9.2.1.6.6 MOEXIPRIL
9.2.1.6.7 OTHERS
9.2.1.7 ORAL HYPOGLYCEMIC THERAPEUTICS
9.2.1.7.1 BIGUANIDES (METFORMIN)
9.2.1.7.2 SULFONYLUREAS
9.2.1.7.2.1 GLIPIZIDE
9.2.1.7.2.2 GLIMEPIRIDE
9.2.1.7.2.3 GLYBURIDE
9.2.1.7.2.4 OTHERS
9.2.1.7.3 THIAZOLIDINEDIONES
9.2.1.7.4 MEGLITINIDES
9.2.2 LIFESTYLE THERAPY
9.2.2.1 PHYSICAL THERAPY
9.2.2.2 SPEECH THERAPY
9.2.2.3 PALLIATIVE CARE
9.2.2.4 OTHERS
9.2.3 SUPPORTIVE DEVICES
9.2.3.1 WALKING AIDS
9.2.3.2 WHEELCHAIRS
9.2.3.3 OTHERS
9.3 DIAGNOSTICS
9.3.1 IMAGING TEST
9.3.1.1 MRI SCAN
9.3.1.2 OTHERS
9.3.2 BLOOD TEST
9.3.3 GENETIC TESTING
10 ASIA PACIFIC ATAXIA MARKET, BY DOSAGE FORM
10.1 OVERVIEW
10.2 SOLID
10.2.1 TABLETS
10.2.2 CAPSULES
10.2.3 OTHERS
10.3 LIQUIDS
10.3.1 INJECTION
10.3.2 SOLUTIONS
10.3.3 OTHERS
10.4 OTHERS
11 ASIA PACIFIC ATAXIA MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.3 PARENTERAL
11.4 OTHERS
12 ASIA PACIFIC ATAXIA MARKET, BY PATIENT TYPE
12.1 OVERVIEW
12.2 ADULT
12.2.1 MALE
12.2.2 FEMALE
12.3 CHILD
12.4 GERIATRIC
13 ASIA PACIFIC ATAXIA MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITAL
13.3 CLINICS
13.4 HOME HEALTHCARE
13.5 OTHERS
14 ASIA PACIFIC ATAXIA MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDER
14.3 RETAIL SALES
14.3.1 HOSPITAL PHARMACY
14.3.2 RETAIL SHOP
14.3.3 ONLINE PHARMACY
14.4 OTHERS
15 ASIA PACIFIC ATAXIA MARKET, BY GEOGRAPHY
15.1 ASIA-PACIFIC
15.1.1 CHINA
15.1.2 JAPAN
15.1.3 INDIA
15.1.4 SOUTH KOREA
15.1.5 AUSTRALIA
15.1.6 SINGAPORE
15.1.7 THAILAND
15.1.8 MALAYSIA
15.1.9 INDONESIA
15.1.10 PHILIPPINES
15.1.11 VIETNAM
15.1.12 RESTF OF ASIA-PACIFIC
16 ASIA PACIFIC ATAXIA MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 SELECT MEDICAL CORPORATION
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 PFIZER INC.
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 NOVARTIS AG
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.4 AMNEAL PHARMACEUTICALS LLC.
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLI
18.4.5 RECENT DEVELOPMENT
18.5 UPSTREAM REHABILITATION INC.
18.5.1 COMPANY SNAPSHOT
18.5.2 COMPANY SHARE ANALYSIS
18.5.3 PRODUCT PORTFOLIO
18.5.4 RECENT DEVELOPMENT
18.6 PRIORY
18.6.1 COMPANY SNAPSHOT
18.6.2 COMPANY SHARE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENT
18.7 ACORDA THERAPEUTICS, INC.
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENTS
18.8 ADVERUM BIOTECHNOLOGIES, INC.
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENT
18.9 APOTEX INC.
18.9.1 COMPANY SNAPSHOT
18.9.2 PRODUCT PORTFOLIO
18.9.3 RECENT DEVELOPMENT
18.1 ATI PHYSICAL THERAPY
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 AUROBINDO PHARMA
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENT
18.12 BANNER HEALTH
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENT
18.13 BIOHAVEN PHARMACEUTICALS
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENTS
18.14 BIOVISTA
18.14.1 COMPANY SNAPSHOT
18.14.2 PRODUCT PORTFOLIO
18.14.3 RECENT DEVELOPMENT
18.15 CIPLA INC.
18.15.1 COMPANY SNAPSHOT
18.15.2 REVENUE ANALYSIS
18.15.3 PRODUCT PORTFOLIO
18.15.4 RECENT DEVELOPMENT
18.16 DESIGN THERAPEUTICS, INC.
18.16.1 COMPANY SNAPSHOT
18.16.2 PRODUCT PORTFOLIO
18.16.3 RECENT DEVELOPMENT
18.17 INTRABIO
18.17.1 COMPANY SNAPSHOT
18.17.2 PRODUCT PORTFOLIO
18.17.3 RECENT DEVELOPMENT
18.18 LUPIN.
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENTS
18.19 MATRIX BIOMED
18.19.1 COMPANY SNAPSHOT
18.19.2 PRODUCT PORTFOLIO
18.19.3 RECENT DEVELOPMENT
18.2 MERCK KGAA
18.20.1 COMPANY SNAPSHOT
18.20.2 REVENUE ANALYSIS
18.20.3 PRODUCT PORTFOLIO
18.20.4 RECENT DEVELOPMENTS
18.21 REATA PHARMACEUTICALS, INC.
18.21.1 COMPANY SNAPSHOT
18.21.2 PRODUCT PORTFOLIO
18.21.3 RECENT DEVELOPMENT
18.22 RETROTOPE INC.
18.22.1 COMPANY SNAPSHOT
18.22.2 PRODUCT PORTFOLIO
18.22.3 RECENT DEVELOPMENT
18.23 SANOFI
18.23.1 COMPANY SNAPSHOT
18.23.2 REVENUE ANALYSIS
18.23.3 PRODUCT PORTFOLIO
18.23.4 RECENT DEVELOPMENT
18.24 SUN PHARMACEUTICAL INDUSTRIES LTD.
18.24.1 COMPANY SNAPSHOT
18.24.2 REVENUE ANALYSIS
18.24.3 PRODUCT PORTFOLIO
18.24.4 RECENT DEVELOPMENT
18.25 SUTTER HEALTH
18.25.1 COMPANY SNAPSHOT
18.25.2 PRODUCT PORTFOLIO
18.25.3 RECENT DEVELOPMENTS
18.26 TEVA PHARMACEUTICAL INDUSTRIES LTD.
18.26.1 COMPANY SNAPSHOT
18.26.2 REVENUE ANALYSIS
18.26.3 PRODUCT PORTFOLIO
18.26.4 RECENT DEVELOPMENT
18.27 VIATRIS INC.
18.27.1 COMPANY SNAPSHOT
18.27.2 REVENUE ANALYSIS
18.27.3 PRODUCT PORTFOLIO
18.27.4 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
表のリスト
TABLE 1 ASIA PACIFIC ATAXIA MARKET: PIPELINE ANALYSIS
TABLE 2 ASIA PACIFIC ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 3 ASIA PACIFIC SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 4 ASIA PACIFIC SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 5 ASIA PACIFIC ATAXIA-TELANGIECTASIA IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 6 ASIA PACIFIC EPISODIC ATAXIA IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 7 ASIA PACIFIC OTHERS (MULTIPLE SYSTEM ATROPHY (MSA)) IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 8 ASIA PACIFIC ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 9 ASIA PACIFIC TREATMENT IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 10 ASIA PACIFIC TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 11 ASIA PACIFIC PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 12 ASIA PACIFIC STIFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 13 ASIA PACIFIC GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 14 ASIA PACIFIC ANTI- OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 15 ASIA PACIFIC NON ANTI- OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 16 ASIA PACIFIC ANTI- ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 17 ASIA PACIFIC ANTI- CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 18 ASIA PACIFIC ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 19 ASIA PACIFIC SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 20 ASIA PACIFIC LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 21 ASIA PACIFIC SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 22 ASIA PACIFIC DIAGNOSTICS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 23 ASIA PACIFIC DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 24 ASIA PACIFIC IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 25 ASIA PACIFIC ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 26 ASIA PACIFIC SOLID IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 27 ASIA PACIFIC SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 28 ASIA PACIFIC LIQUIDS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 29 ASIA PACIFIC LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 30 ASIA PACIFIC OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 31 ASIA PACIFIC ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 32 ASIA PACIFIC ORAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 33 ASIA PACIFIC PARENTERAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 34 ASIA PACIFIC OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 35 ASIA PACIFIC ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 36 ASIA PACIFIC ADULT IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 37 ASIA PACIFIC ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 38 ASIA PACIFIC CHILD IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 39 ASIA PACIFIC GERIATRIC IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 40 ASIA PACIFIC ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 41 ASIA PACIFIC HOSPITAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 42 ASIA PACIFIC CLINICS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 43 ASIA PACIFIC HOME HEALTHCARE IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 44 ASIA PACIFIC OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 45 ASIA PACIFIC ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 46 ASIA PACIFIC DIRECT TENDER IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 47 ASIA PACIFIC RETAIL SALES IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 48 ASIA PACIFIC RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 49 ASIA PACIFIC OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 50 ASIA-PACIFIC ATAXIA MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)
TABLE 51 ASIA-PACIFIC ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 52 ASIA-PACIFIC SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 53 ASIA-PACIFIC ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 54 ASIA-PACIFIC TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 55 ASIA-PACIFIC PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 56 ASIA-PACIFIC STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 57 ASIA-PACIFIC GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 58 ASIA-PACIFIC ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 59 ASIA-PACIFIC NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 60 ASIA-PACIFIC ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 61 ASIA-PACIFIC ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 62 ASIA-PACIFIC ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 63 ASIA-PACIFIC SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 64 ASIA-PACIFIC LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 65 ASIA-PACIFIC SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 66 ASIA-PACIFIC DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 67 ASIA-PACIFIC IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 68 ASIA-PACIFIC IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 69 ASIA-PACIFIC SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 70 ASIA-PACIFIC LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 71 ASIA-PACIFIC ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 72 ASIA-PACIFIC ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 73 ASIA-PACIFIC ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 74 ASIA-PACIFIC ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 75 ASIA-PACIFIC ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 76 ASIA-PACIFIC RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 77 CHINA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 78 CHINA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 79 CHINA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 80 CHINA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 81 CHINA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 82 CHINA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 83 CHINA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 84 CHINA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 85 CHINA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 86 CHINA ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 87 CHINA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 88 CHINA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 89 CHINA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 90 CHINA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 91 CHINA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 92 CHINA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 93 CHINA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 94 CHINA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 95 CHINA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 96 CHINA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 97 CHINA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 98 CHINA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 99 CHINA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 100 CHINA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 101 CHINA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 102 CHINA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 103 JAPAN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 104 JAPAN SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 105 JAPAN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 106 JAPAN TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 107 JAPAN PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 108 JAPAN STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 109 JAPAN GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 110 JAPAN ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 111 JAPAN NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 112 JAPAN ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 113 JAPAN ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 114 JAPAN ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 115 JAPAN SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 116 JAPAN LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 117 JAPAN SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 118 JAPAN DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 119 JAPAN IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 120 JAPAN IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 121 JAPAN SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 122 JAPAN LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 123 JAPAN ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 124 JAPAN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 125 JAPAN ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 126 JAPAN ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 127 JAPAN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 128 JAPAN RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 129 INDIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 130 INDIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 131 INDIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 132 INDIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 133 INDIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 134 INDIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 135 INDIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 136 INDIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 137 INDIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 138 INDIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 139 INDIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 140 INDIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 141 INDIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 142 INDIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 143 INDIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 144 INDIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 145 INDIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 146 INDIA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 147 INDIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 148 INDIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 149 INDIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 150 INDIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 151 INDIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 152 INDIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 153 INDIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 154 INDIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 155 SOUTH KOREA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 156 SOUTH KOREA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 157 SOUTH KOREA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 158 SOUTH KOREA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 159 SOUTH KOREA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 160 SOUTH KOREA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 161 SOUTH KOREA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 162 SOUTH KOREA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 163 SOUTH KOREA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 164 SOUTH KOREA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 165 SOUTH KOREA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 166 SOUTH KOREA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 167 SOUTH KOREA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 168 SOUTH KOREA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 169 SOUTH KOREA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 170 SOUTH KOREA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 171 SOUTH KOREA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 172 SOUTH KOREA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 173 SOUTH KOREA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 174 SOUTH KOREA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 175 SOUTH KOREA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 176 SOUTH KOREA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 177 SOUTH KOREA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 178 SOUTH KOREA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 179 SOUTH KOREA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 180 SOUTH KOREA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 181 AUSTRALIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 182 AUSTRALIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 183 AUSTRALIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 184 AUSTRALIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 185 AUSTRALIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 186 AUSTRALIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 187 AUSTRALIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 188 AUSTRALIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 189 AUSTRALIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 190 AUSTRALIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 191 AUSTRALIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 192 AUSTRALIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 193 AUSTRALIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 194 AUSTRALIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 195 AUSTRALIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 196 AUSTRALIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 197 AUSTRALIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 198 AUSTRALIA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 199 AUSTRALIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 200 AUSTRALIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 201 AUSTRALIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 202 AUSTRALIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 203 AUSTRALIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 204 AUSTRALIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 205 AUSTRALIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 206 AUSTRALIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 207 SINGAPORE ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 208 SINGAPORE SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 209 SINGAPORE ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 210 SINGAPORE TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 211 SINGAPORE PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 212 SINGAPORE STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 213 SINGAPORE GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 214 SINGAPORE ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 215 SINGAPORE NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 216 SINGAPORE ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 217 SINGAPORE ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 218 SINGAPORE ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 219 SINGAPORE SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 220 SINGAPORE LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 221 SINGAPORE SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 222 SINGAPORE DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 223 SINGAPORE IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 224 SINGAPORE IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 225 SINGAPORE SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 226 SINGAPORE LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 227 SINGAPORE ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 228 SINGAPORE ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 229 SINGAPORE ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 230 SINGAPORE ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 231 SINGAPORE ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 232 SINGAPORE RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 233 THAILAND ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 234 THAILAND SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 235 THAILAND ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 236 THAILAND TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 237 THAILAND PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 238 THAILAND STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 239 THAILAND GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 240 THAILAND ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 241 THAILAND NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 242 THAILAND ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 243 THAILAND ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 244 THAILAND ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 245 THAILAND SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 246 THAILAND LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 247 THAILAND SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 248 THAILAND DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 249 THAILAND IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 250 THAILAND IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 251 THAILAND SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 252 THAILAND LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 253 THAILAND ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 254 THAILAND ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 255 THAILAND ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 256 THAILAND ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 257 THAILAND ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 258 THAILAND RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 259 MALAYSIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 260 MALAYSIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 261 MALAYSIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 262 MALAYSIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 263 MALAYSIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 264 MALAYSIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 265 MALAYSIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 266 MALAYSIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 267 MALAYSIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 268 MALAYSIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 269 MALAYSIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 270 MALAYSIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 271 MALAYSIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 272 MALAYSIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 273 MALAYSIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 274 MALAYSIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 275 MALAYSIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 276 MALAYSIA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 277 MALAYSIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 278 MALAYSIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 279 MALAYSIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 280 MALAYSIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 281 MALAYSIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 282 MALAYSIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 283 MALAYSIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 284 MALAYSIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 285 INDONESIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 286 INDONESIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 287 INDONESIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 288 INDONESIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 289 INDONESIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 290 INDONESIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 291 INDONESIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 292 INDONESIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 293 INDONESIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 294 INDONESIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 295 INDONESIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 296 INDONESIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 297 INDONESIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 298 INDONESIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 299 INDONESIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 300 INDONESIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 301 INDONESIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 302 INDONESIA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 303 INDONESIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 304 INDONESIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 305 INDONESIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 306 INDONESIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 307 INDONESIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 308 INDONESIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 309 INDONESIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 310 INDONESIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 311 PHILIPPINES ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 312 PHILIPPINES SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 313 PHILIPPINES ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 314 PHILIPPINES TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 315 PHILIPPINES PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 316 PHILIPPINES STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 317 PHILIPPINES GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 318 PHILIPPINES ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 319 PHILIPPINES NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 320 PHILIPPINES ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 321 PHILIPPINES ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 322 PHILIPPINES ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 323 PHILIPPINES SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 324 PHILIPPINES LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 325 PHILIPPINES SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 326 PHILIPPINES DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 327 PHILIPPINES IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 328 PHILIPPINES IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 329 PHILIPPINES SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 330 PHILIPPINES LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 331 PHILIPPINES ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 332 PHILIPPINES ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 333 PHILIPPINES ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 334 PHILIPPINES ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 335 PHILIPPINES ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 336 PHILIPPINES RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 337 VIETNAM ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 338 VIETNAM SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 339 VIETNAM ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 340 VIETNAM TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 341 VIETNAM PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 342 VIETNAM STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 343 VIETNAM GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 344 VIETNAM ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 345 VIETNAM NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 346 VIETNAM ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 347 VIETNAM ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 348 VIETNAM ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 349 VIETNAM SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 350 VIETNAM LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 351 VIETNAM SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 352 VIETNAM DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 353 VIETNAM IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 354 VIETNAM IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 355 VIETNAM SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 356 VIETNAM LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 357 VIETNAM ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 358 VIETNAM ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 359 VIETNAM ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 360 VIETNAM ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 361 VIETNAM ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 362 VIETNAM RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 363 RESTF OF ASIA-PACIFIC ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
図表一覧
FIGURE 1 ASIA PACIFIC ATAXIA MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC ATAXIA MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC ATAXIA MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC ATAXIA MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC ATAXIA MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC ATAXIA MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC ATAXIA MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA PACIFIC ATAXIA MARKET: END USER COVERAGE GRID
FIGURE 9 ASIA PACIFIC ATAXIA MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC ATAXIA MARKET: SEGMENTATION
FIGURE 11 RAPID RESEARCH IN FIELD OF ATAXIA THEREPEUTICS IS EXPECTED TO DRIVE THE ASIA PACIFIC ATAXIA MARKET IN THE FORECAST PERIOD
FIGURE 12 SPINOCEREBELLAR ATAXIAS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC ATAXIA MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE ASIA PACIFIC ATAXIA MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC ATAXIA MARKET
FIGURE 15 ASIA PACIFIC ATAXIA MARKET: BY TYPE, 2021
FIGURE 16 ASIA PACIFIC ATAXIA MARKET: BY TYPE, 2022-2029 (USD THOUSAND)
FIGURE 17 ASIA PACIFIC ATAXIA MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 18 ASIA PACIFIC ATAXIA MARKET: BY TYPE, LIFELINE CURVE
FIGURE 19 ASIA PACIFIC ATAXIA MARKET: BY PRODUCT, 2021
FIGURE 20 ASIA PACIFIC ATAXIA MARKET: BY PRODUCT, 2022-2029 (USD THOUSAND)
FIGURE 21 ASIA PACIFIC ATAXIA MARKET: BY PRODUCT, CAGR (2022-2029)
FIGURE 22 ASIA PACIFIC ATAXIA MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 23 ASIA PACIFIC ATAXIA MARKET: BY DOSAGE FORM, 2021
FIGURE 24 ASIA PACIFIC ATAXIA MARKET: BY DOSAGE FORM, 2022-2029 (USD THOUSAND)
FIGURE 25 ASIA PACIFIC ATAXIA MARKET: BY DOSAGE FORM, CAGR (2022-2029)
FIGURE 26 ASIA PACIFIC ATAXIA MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 27 ASIA PACIFIC ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 28 ASIA PACIFIC ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD THOUSAND)
FIGURE 29 ASIA PACIFIC ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 30 ASIA PACIFIC ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 31 ASIA PACIFIC ATAXIA MARKET: BY PATIENT TYPE, 2021
FIGURE 32 ASIA PACIFIC ATAXIA MARKET: BY PATIENT TYPE, 2022-2029 (USD THOUSAND)
FIGURE 33 ASIA PACIFIC ATAXIA MARKET: BY PATIENT TYPE, CAGR (2022-2029)
FIGURE 34 ASIA PACIFIC ATAXIA MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 35 ASIA PACIFIC ATAXIA MARKET: BY END USER, 2021
FIGURE 36 ASIA PACIFIC ATAXIA MARKET: BY END USER, 2022-2029 (USD THOUSAND)
FIGURE 37 ASIA PACIFIC ATAXIA MARKET: BY END USER, CAGR (2022-2029)
FIGURE 38 ASIA PACIFIC ATAXIA MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 ASIA PACIFIC ATAXIA MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 40 ASIA PACIFIC ATAXIA MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD THOUSAND)
FIGURE 41 ASIA PACIFIC ATAXIA MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 42 ASIA PACIFIC ATAXIA MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 ASIA-PACIFIC ATAXIA MARKET: SNAPSHOT (2021)
FIGURE 44 ASIA-PACIFIC ATAXIA MARKET: BY COUNTRY (2021)
FIGURE 45 ASIA-PACIFIC ATAXIA MARKET: BY COUNTRY (2022 & 2029)
FIGURE 46 ASIA-PACIFIC ATAXIA MARKET: BY COUNTRY (2021 & 2029)
FIGURE 47 ASIA-PACIFIC ATAXIA MARKET: BY TYPE (2022-2029)
FIGURE 48 ASIA PACIFIC ATAXIA MARKET: COMPANY SHARE 2021 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。